NexImmune (NASDAQ:NEXI) Stock Rating Lowered by Cantor Fitzgerald

Cantor Fitzgerald downgraded shares of NexImmune (NASDAQ:NEXIGet Rating) from an overweight rating to a neutral rating in a report released on Wednesday, The Fly reports. Cantor Fitzgerald also issued estimates for NexImmune’s FY2022 earnings at ($2.52) EPS and FY2023 earnings at ($0.93) EPS.

A number of other equities analysts also recently commented on the stock. Raymond James downgraded shares of NexImmune from an outperform rating to a market perform rating in a report on Tuesday, November 15th. Barclays reduced their price objective on shares of NexImmune from $7.00 to $2.00 and set an overweight rating for the company in a report on Tuesday, August 16th.

NexImmune Price Performance

Shares of NEXI opened at $0.45 on Wednesday. The company’s fifty day moving average is $0.64 and its 200-day moving average is $1.33. NexImmune has a 12 month low of $0.43 and a 12 month high of $10.38. The firm has a market cap of $10.87 million, a price-to-earnings ratio of -0.17 and a beta of 1.95.

Insider Activity at NexImmune

In related news, Director Sol J. Barer acquired 125,000 shares of the stock in a transaction on Wednesday, November 16th. The stock was purchased at an average price of $0.48 per share, for a total transaction of $60,000.00. Following the transaction, the director now owns 1,742,814 shares of the company’s stock, valued at approximately $836,550.72. The acquisition was disclosed in a filing with the SEC, which is available through this link. 18.50% of the stock is currently owned by insiders.

Institutional Investors Weigh In On NexImmune

Several institutional investors have recently modified their holdings of the business. Smith Salley & Associates bought a new position in NexImmune during the 1st quarter worth approximately $46,000. Bailard Inc. bought a new position in NexImmune in the second quarter valued at approximately $33,000. Raymond James & Associates bought a new position in NexImmune in the first quarter valued at approximately $87,000. Sei Investments Co. bought a new position in NexImmune in the second quarter valued at approximately $43,000. Finally, Goldman Sachs Group Inc. bought a new position in NexImmune in the second quarter valued at approximately $47,000. Institutional investors and hedge funds own 34.45% of the company’s stock.

NexImmune Company Profile

(Get Rating)

NexImmune, Inc, a clinical-stage biotechnology company, engages in developing therapies with curative potential for patients with cancer and other life-threatening immune-mediated diseases. It develops approaches to T cell immunotherapies based on its proprietary Artificial Immune Modulation, a nanoparticle technology platform.

Featured Stories

The Fly logo

Receive News & Ratings for NexImmune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NexImmune and related companies with's FREE daily email newsletter.